CEO
Jon Heimer
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Olink Holding AB provides accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients.
Loading...
Open
26.00
Mkt cap
3.2B
Volume
1.9M
High
26.08
P/E Ratio
-96.59
52-wk high
26.09
Low
25.98
Div yield
N/A
52-wk low
14.10
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.